Bio Roundup: ASCO Abstracts, Migraine Drug Prices & “Blueprint” Fallout
Xconomy
MAY 18, 2018
There’s nothing abstract about a 20 percent jump in a company’s stock price. But yeah, that happened to Loxo Oncology when it released data previews for its American Society for Clinical Oncology presentations; the meeting starts in two weeks in Chicago. Read more » Reprints | Share:
Let's personalize your content